Document is current
Any future updates will be listed below
-
Authors
Knobloch, Gesine
Nagle, Scott
Colgan, Timothy
Schubert, Tilman
Johnson, Kevin M.
Bannas, Peter
Li, Geng
Hinshaw, Louis
Holmes, James
Reeder, Scott B.
-
Funding
Funding for this research was provided by:
National Institutes of Health (K24 DK102595, T32CA009206)
Departments of Radiology and Medical Physics, University of Wisconsin
- License Information
-
More Information
Article History
First Online: 13 June 2020
Compliance with ethical standards
:
: The authors have no relevant conflict of interest. Dr. Reeder consults for ArTara Therapeutics, and has ownership interests in Calimetrix, Reveal Pharmaceuticals, Cellectar Biosciences, and Elucent Medical. Unrelated disclosures of Scott Nagle include consulting for Vertex Pharmaceuticals. Gesine Knobloch is currently an employee at Bayer AG, Berlin, Germany. The University of Wisconsin receives research support from General Electrics Healthcare and Bracco Diagnostics. This specific project was supported by the Departments of Radiology and Medical Physics, at the University of Wisconsin, and the National Institute of Health (NIH, K24 DK102595 and T32CA009206). Furthermore, this project received statistical supported through the Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS), grant UL1TR002373. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
